{"id":2398,"date":"2026-10-16T21:45:12","date_gmt":"2026-10-16T13:45:12","guid":{"rendered":"http:\/\/www.puriactives.com\/en\/?p=2398"},"modified":"2026-10-16T21:45:12","modified_gmt":"2026-10-16T13:45:12","slug":"puriactives-crystal-retinal","status":"publish","type":"post","link":"http:\/\/www.puriactives.com\/en\/?p=2398","title":{"rendered":"PuriActives\u00ae Crystal Retinal"},"content":{"rendered":"

PuriActives\u00ae Crystal RetinalCyclodextrin-Included Retinal<\/p>\n

PuriPharm Co., Ltd. \u00b7 Retinal science<\/p>\n

PuriActives\u00ae Crystal Retinal Cyclodextrin-Included Retinal<\/b><\/h2>\n

\"\"<\/p>\n

High-performance retinal through molecular inclusion science<\/p>\n

Retinal \u00b7 Cyclodextrin inclusion \u00b7 Skin and scalp renewal<\/b><\/p>\n

Scientific and technical report for cosmetic formulators and brand R&D teams<\/p>\n

PART I \u00b7 NEXT-GENERATION RETINAL<\/p>\n

The evolution of vitamin A skincare<\/b><\/h2>\n

RETINYL ESTERS<\/p>\n

Storage forms requiring hydrolysis before entering metabolism.<\/p>\n

RETINOL<\/p>\n

An established cosmetic benchmark, oxidized to retinal in skin.<\/p>\n

RETINAL (RAL)<\/p>\n

One oxidation step from retinoic acid: its direct metabolic precursor.<\/p>\n

RETINOIC ACID<\/p>\n

The receptor-active form; prescription-only in many markets.<\/p>\n

Esterases \u00b7 Retinol dehydrogenases (RDH\/ADH) \u00b7 Retinaldehyde dehydrogenases (ALDH1A)<\/p>\n

FROM STORAGE FORM TO SIGNALING MOLECULE<\/b><\/p>\n

Cosmetic vitamin A ingredients follow the skin\u2019s own metabolic pathway. Moving closer to retinoic acid reduces the number of enzymatic conversions.<\/p>\n

Retinal is the direct biosynthetic precursor of retinoic acid, the active form that binds nuclear retinoid receptors and drives epidermal renewal.<\/p>\n

Metabolic proximity is a mechanistic rationale, not a clinical conclusion. Relative efficacy requires controlled human studies, reviewed in Part III.<\/p>\n

2 \u2192 1<\/p>\n

Oxidation steps to retinoic acid: two for retinol, one for retinal.<\/p>\n

1994<\/p>\n

Topical retinal was first biologically characterized in human skin (Saurat et al.).<\/p>\n

125+<\/p>\n

Participants indicated in the source\u2019s milestone vehicle-controlled profilometry trial comparing retinal with retinoic acid (1998).<\/p>\n

Saurat JH et al. J Invest Dermatol. 1994;103(6):770\u2013774. Creidi P et al. J Am Acad Dermatol. 1998;39(6):960\u2013965. Retinoid metabolism: RDH\/ADH and ALDH1A enzyme families.<\/p>\n

PART I \u00b7 NEXT-GENERATION RETINAL<\/p>\n

One conversion from retinoic acid: retinal biology<\/b><\/h2>\n

All-trans-retinal (C20H28O; molecular weight 284.4)<\/b><\/p>\n

\"\"<\/p>\n

The \u03b2-ionone ring, conjugated polyene chain and terminal aldehyde underlie both biological activity and chemical vulnerability.<\/p>\n

The conjugated system responsible for sensitivity to light and oxidation also contributes to retinal\u2019s biological activity.<\/p>\n

Stabilizing this molecule without changing its chemistry is the formulation challenge addressed by cyclodextrin inclusion.<\/p>\n

A NATURAL INTERMEDIATE IN VITAMIN A METABOLISM<\/p>\n

Retinal forms from retinol in skin and can convert further to retinoic acid.<\/p>\n

DIRECT PRECURSOR<\/p>\n

One oxidation by retinaldehyde dehydrogenases produces retinoic acid, a ligand for nuclear RAR receptors involved in epidermal gene regulation.<\/p>\n

DOCUMENTED BIOACTIVITY IN HUMAN SKIN<\/p>\n

Early human studies reported measurable effects of topical retinal, including epidermal hyperplasia and increased dermal elastin, with good tolerability.<\/p>\n

THREE DECADES OF CLINICAL LITERATURE<\/p>\n

Human studies since 1994 have assessed texture, wrinkles, elasticity, tone, hydration and tolerability.<\/p>\n

COSMETIC POSITIONING<\/p>\n

The source identifies retinal (INCI: RETINAL) as a cosmetic retinoid, in contrast to retinoic acid, supporting science-led formulation development.<\/p>\n

Saurat JH et al. J Invest Dermatol. 1994;103(6):770\u2013774. Sorg O, Saurat JH. Dermatology. 2014;228(4):314\u2013325. Formula and molecular weight: PubChem CID 638015.<\/p>\n

PART I \u00b7 NEXT-GENERATION RETINAL<\/p>\n

High potential with demanding formulation requirements<\/b><\/h2>\n

Retinal\u2019s conjugated polyene chain and terminal aldehyde are chemically reactive. In conventional formulations, degradation through several documented pathways can reduce the available active.<\/p>\n

PHOTOCHEMICAL SENSITIVITY<\/p>\n

UV and visible light induce polyene photoisomerization and photodegradation.<\/p>\n

OXIDATIVE DEGRADATION<\/p>\n

Autoxidation of the conjugated chain generates peroxide intermediates and breakdown products.<\/p>\n

THERMAL INSTABILITY<\/p>\n

Heat accelerates degradation, affecting manufacturing, transport and shelf life.<\/p>\n

ISOMERIZATION<\/p>\n

Light and heat can convert the all-trans form into cis isomers with altered biological activity.<\/p>\n

VERY LOW WATER SOLUBILITY<\/p>\n

The lipophilic molecule is difficult to disperse uniformly in aqueous and emulsified systems.<\/p>\n

ACTIVE RETENTION IN FORMULATIONS<\/p>\n

Interactions with oils, surfactants and packaging may reduce the retinal available at the point of use.<\/p>\n

PATENT STRESS TESTS<\/p>\n

Under accelerated UV aging (200\u2013400 nm, 48 hours), an unstabilized retinal gel faded from deep yellow toward near-complete degradation, with a color score of 1\/20. Under thermal stress (45 \u00b0C, 7 days), the unstabilized group showed complete degradation, scored 20\/20.<\/p>\n

US 10,864,148 B2 (2020), Example 3, Table 6: visual color-scoring degradation tests of retinal formulations.<\/p>\n

Selecting retinal is the first step. Its molecular environment determines how it can be formulated.<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Introducing PuriActives\u00ae Crystal Retinal Cyclodextrin-Included Retinal<\/b><\/h2>\n

A cyclodextrin-included retinal system designed around molecular stabilization and formulation flexibility, connecting retinal biology with host\u2013guest chemistry.<\/p>\n

PRODUCT<\/p>\n

PuriActives\u00ae Crystal Retinal Cyclodextrin-Included Retinal<\/p>\n

INCI NAME<\/p>\n

RETINAL<\/p>\n

CORE TECHNOLOGY<\/p>\n

Cyclodextrin molecular inclusion<\/p>\n

APPLICATIONS<\/p>\n

Premium skincare and science-led scalp care<\/p>\n

RETINAL BIOLOGY<\/p>\n

The direct metabolic precursor of retinoic acid, supported by three decades of human research.<\/p>\n

MOLECULAR INCLUSION<\/p>\n

Cyclodextrin host\u2013guest chemistry provides a protective environment for a vulnerable active.<\/p>\n

FORMULATION INNOVATION<\/p>\n

A solid, dispersible ingredient format opens formulation routes that are difficult for free retinal.<\/p>\n

Designed for formulators seeking a stabilization strategy at the ingredient level while retaining retinal\u2019s biological identity.<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Cyclodextrins: molecular architecture from starch<\/b><\/h2>\n

Cyclodextrins are cyclic oligosaccharides produced by enzymatic conversion of starch. Their truncated-cone geometry creates a relatively hydrophilic exterior and a relatively hydrophobic cavity suited to lipophilic guests such as retinoids.<\/p>\n

\u03b1-CYCLODEXTRIN<\/p>\n

6 glucopyranose units; the smallest cavity, approximately 4.7\u20135.3 \u00c5.<\/p>\n

\"\"<\/p>\n

\u03b2-CYCLODEXTRIN<\/p>\n

7 glucopyranose units; a medium cavity, approximately 6.0\u20136.5 \u00c5.<\/p>\n

\"\"<\/p>\n

\u03b3-CYCLODEXTRIN<\/p>\n

8 glucopyranose units; the largest cavity, approximately 7.5\u20138.3 \u00c5.<\/p>\n

Cavity size affects which guests enter and how they are accommodated. In cited vitamin A tests, the larger \u03b3-cyclodextrin cavity provided greater protection than \u03b2-cyclodextrin, making cavity geometry an important formulation variable.<\/p>\n

After 48 days of UVA stress, a retinol\/\u03b3-CD complex retained 18.0% retinol, while the corresponding \u03b2-CD complex retained none (US 5,985,296, Example 3, Table 1).<\/p>\n

Structure figures: US 8,410,079 B2 (2013), Figures 1\u20133. Cavity dimensions: Loftsson T, Brewster ME. J Pharm Sci. 1996;85(10):1017\u20131025.<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Molecular inclusion: a protective environment for retinal<\/b><\/h2>\n

\"\"<\/p>\n

HOST\u2013GUEST ASSOCIATION: SCHEMATIC<\/b><\/p>\n

Cyclodextrin host: hydrophilic exterior<\/b><\/p>\n

Hydrophobic<\/p>\n

cavity<\/p>\n

Retinal guest<\/b><\/p>\n

Noncovalent association: the guest is accommodated, not chemically modified.<\/p>\n

DYNAMIC EQUILIBRIUM<\/p>\n

Included retinal \u21cc Free retinal. As free retinal is taken up by skin during use, the equilibrium replenishes available active.<\/p>\n

HOST\u2013GUEST ASSOCIATION<\/p>\n

Hydrophobic and van der Waals interactions drive lipophilic guests into the nonpolar cavity.<\/p>\n

REDUCED ENVIRONMENTAL EXPOSURE<\/p>\n

The included fraction has reduced exposure to bulk solvent, oxygen and light, key contributors to retinal degradation.<\/p>\n

DISPERSION AND HANDLING<\/p>\n

A lipophilic crystalline active becomes a water-dispersible solid ingredient for easier weighing, dispersion and processing.<\/p>\n

EQUILIBRIUM-DRIVEN AVAILABILITY<\/p>\n

Guest release follows the association equilibrium without shell rupture or a triggered chemical reaction.<\/p>\n

DISTINCT FROM COVALENT DERIVATIVES<\/p>\n

Inclusion is a physical association. The retinal\u2013cyclodextrin hemiacetals discussed in the patent section are covalently bonded molecules of another class.<\/p>\n

Loftsson T, Brewster ME. J Pharm Sci. 1996;85(10):1017\u20131025. Yap KL et al. Eur J Pharm Sci. 2005;25(1):49\u201356. Schematic for illustration; partial inclusion geometries of polyene guests have been reported.<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Stability through molecular design: interpreting stress tests<\/b><\/h2>\n

RETINOL RETENTION DURING OPEN STORAGE IN DAYLIGHT AT ROOM TEMPERATURE<\/p>\n

Intact retinol measured by HPLC relative to day 0. US 5,985,296, Example 4, Table 2.<\/p>\n

\"\"<\/p>\n

UVA AT 366 NM FOR 48 DAYS<\/p>\n

18.0% retinol retained in the \u03b3-CD complex<\/p>\n

0% retained in the \u03b2-CD complex under the same conditions<\/p>\n

US 5,985,296, Example 3, Table 1.<\/b><\/p>\n

Protection depends on the molecular environment. In the patent comparisons, the \u03b3-cyclodextrin complex retained most retinol after three weeks of open daylight storage, whereas the lactose triturate lost almost all of it.<\/p>\n

Under UVA stress, \u03b3-CD outperformed the smaller \u03b2-CD cavity, indicating the importance of inclusion geometry.<\/p>\n

These data concern retinol, the immediate precursor of retinal, which shares related conjugated degradation chemistry.<\/p>\n

US 5,985,296 A (Wacker-Chemie, 1999), Examples 3\u20134, Tables 1\u20132. Stability is complex-specific. These results characterize the tested materials and do not represent a particular commercial ingredient.<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Four decades of retinal and cyclodextrin patent science<\/b><\/h2>\n

1983<\/b><\/p>\n

WATER-SOLUBLE RETINOID COMPLEXES<\/p>\n

Retinal\u2013polymer conjugates with cyclodextrin for water-compatible vitamin A systems.<\/p>\n

US 4,371,673 (Pitha): an early approach to water-compatible retinoid delivery.<\/p>\n

1999<\/b><\/p>\n

\u03b3-CD INCLUSION FOR VITAMIN A STABILITY<\/p>\n

Quantified improvements in light and storage stability of retinol\/\u03b3-CD complexes.<\/p>\n

US 5,985,296 (Wacker-Chemie): HPLC comparisons with \u03b2-CD and lactose controls.<\/p>\n

2013<\/b><\/p>\n

RETINAL\u2013CD HEMIACETAL DERIVATIVES<\/p>\n

Covalent retinal\u2013cyclodextrin structures developed for skin-tone applications.<\/p>\n

US 8,410,079 B2: chemically distinct from noncovalent inclusion complexes.<\/p>\n

2020<\/b><\/p>\n

MODERN RETINAL STABILIZATION<\/p>\n

Cyclodextrin-encapsulated retinal combined with antioxidant systems.<\/p>\n

US 10,864,148 B2: thermal and UV stress tests of encapsulated retinal gels.<\/p>\n

WHAT THE PATENT HISTORY SHOWS<\/p>\n

Successive approaches address retinoid instability through solubilization, inclusion, covalent derivatives and integrated formulations. Cyclodextrin inclusion is a route that protects the active without changing its molecular identity.<\/p>\n

\"\"<\/p>\n

General retinal\u2013cyclodextrin acetal structure<\/p>\n

CN 103987391 B, Formula (Ib).<\/p>\n

\"\"<\/p>\n

Exocyclic retinal\u2013CD hemiacetal (VIII)<\/p>\n

EP 2 755 664 B1 \/ HK 1200172 B, page 8.<\/p>\n

US 4,371,673 A (1983) \u00b7 US 5,985,296 A (1999) \u00b7 US 8,410,079 B2 (2013) \u00b7 US 10,864,148 B2 (2020).<\/p>\n

PART II \u00b7 THE SCIENCE OF CRYSTAL RETINAL<\/p>\n

Comparing retinal formulation approaches<\/b><\/h2>\n

Three approaches to retinal formulation involve different practical considerations. This table compares formulation principles rather than ranking performance.<\/p>\n

\"\"<\/p>\n

This is a qualitative comparison of formulation principles. Actual performance depends on the complex, manufacturing process and finished formulation. Validation parameters must be established during product development.<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

From retinal to skin renewal: the signaling cascade<\/b><\/h2>\n

\"\"<\/p>\n

DOCUMENTED IN SKIN<\/b><\/p>\n

RETINAL INCREASES CUTANEOUS RETINOIC ACID<\/p>\n

Topical retinal increased retinoic acid content and retinoid activity in mouse skin, supporting enzymatic conversion within tissue (Didierjean et al., 1996; Sorg et al., 1999).<\/p>\n

HUMAN EPIDERMAL RENEWAL MARKERS<\/p>\n

In human skin, topical retinal induced epidermal hyperplasia and increased dermal elastin with good tolerability, consistent with retinoid-mediated renewal (Saurat et al., 1994).<\/p>\n

RECEPTOR SPECIFICITY<\/p>\n

In human keratinocytes, retinoid signaling at physiological, nanomolar ligand concentrations acts mainly through RAR\u2013RXR heterodimers at \u03b2RARE elements (Xiao et al., 1995).<\/p>\n

DOWNSTREAM VISIBLE ENDPOINTS<\/p>\n

Texture, wrinkles, firmness, tone and barrier quality are mapped to human evidence in the following sections.<\/p>\n

Didierjean L et al. J Invest Dermatol. 1996;107(5):714\u2013719. Sorg O et al. Dermatology. 1999;199(Suppl 1):13\u201317. Saurat JH et al. J Invest Dermatol. 1994;103(6):770\u2013774. Xiao JH et al. J Biol Chem. 1995;270(7):3001\u20133011.<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Skin texture: measurable renewal<\/b><\/h2>\n

Skin-surface refinement is an instrumentally measurable retinoid endpoint. Retinal supports orderly keratinocyte renewal, and changes can be assessed by profilometry and 3D imaging.<\/p>\n

WHY THE SURFACE RESPONDS<\/b><\/p>\n

Retinoic acid generated in skin modulates keratinocyte differentiation and epidermal turnover. Replacement of accumulated, disorganized corneocytes produces a more regular surface, measured as lower roughness in 3D imaging.<\/p>\n

Retinal\u2019s single-step conversion provides a rationale for renewal at cosmetic use concentrations.<\/p>\n

+13.7%<\/p>\n

Texture improvement with 0.1% retinal<\/p>\n

+12.6%<\/p>\n

Texture improvement with 0.05% retinal<\/p>\n

Randomized double-blind trial: 40 women with photoaged skin, twice-daily use for 3 months; texture quantified by Antera 3D imaging.<\/p>\n

BENCHMARK PROFILOMETRY STUDY<\/p>\n

Creidi et al. J Am Acad Dermatol. 1998.<\/p>\n

125 participants \u00b7 44 weeks \u00b7 0.05% retinal<\/b><\/p>\n

DESIGN<\/p>\n

Double-blind comparison of 0.05% retinal, 0.05% retinoic acid and vehicle in photoaged skin, with objective surface profilometry.<\/p>\n

RESULTS<\/p>\n

Both vitamin A groups reduced wrinkles and roughness versus vehicle, with significant improvement from week 18. Efficacy did not differ significantly between the active groups.<\/p>\n

TOLERABILITY<\/p>\n

Retinal was significantly better tolerated than retinoic acid at the same concentration.<\/p>\n

For formulation development, these results support retinal as a cosmetic option with surface efficacy comparable to retinoic acid under the tested conditions. Inclusion provides a stabilization rationale that must be verified in the formulation.<\/p>\n

Kwon HS et al. J Cosmet Dermatol. 2018;17(3):471\u2013476. Creidi P et al. J Am Acad Dermatol. 1998;39(6):960\u2013965. Studies used finished creams; results characterize the retinal active class.<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Wrinkles and fine lines: clinical evidence<\/b><\/h2>\n

TWELVE WEEKS, TWO CONCENTRATIONS, FOUR ENDPOINTS<\/p>\n

Percentage change from baseline; randomized double-blind trial; 40 women; twice-daily use.<\/p>\n

\"\"<\/p>\n

All displayed changes were significant versus baseline except the 0.05% group\u2019s melanin endpoint, which was not significant and is therefore shown without a bar. Lower TEWL and melanin index indicate improvement.<\/p>\n

LONG-TERM CONTROLLED EVIDENCE<\/p>\n

Week 18: significant reduction versus vehicle<\/p>\n

44-week follow-up; n = 125<\/p>\n

Creidi P et al. J Am Acad Dermatol. 1998.<\/b><\/p>\n

At the same 0.05% concentration, retinal provided wrinkle improvement comparable to retinoic acid by profilometry, with significantly less irritation.<\/p>\n

The response persisted through the 44-week observation period, supporting a sustained rather than transient surface effect.<\/p>\n

DOSE-SELECTION RATIONALE<\/p>\n

In the reported results, 0.1% showed greater texture and pigment changes, while 0.05% showed the greater TEWL reduction. These endpoints inform different formulation concepts.<\/p>\n

Kwon HS et al. J Cosmet Dermatol. 2018;17(3):471\u2013476 (randomized double-blind trial, n = 40, 3 months; Antera 3D, corneometry, TEWL and pigment measurement). Creidi P et al. J Am Acad Dermatol. 1998;39(6):960\u2013965 (n = 125, 44 weeks; profilometry).<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Dermal matrix: collagen and elastic-fiber support<\/b><\/h2>\n

Photoaging involves disrupted collagen and elastic fibers. Histology in skin explants and instrumental measurements in vivo provide evidence relevant to retinal and matrix-related care.<\/p>\n

HUMAN SKIN EXPLANTS: UVA REPAIR MODEL<\/b><\/p>\n

Fibers restored toward unexposed levels<\/b><\/p>\n

Human skin explants were photoaged with UVA in organ culture and treated with 0.05% retinal cream for 2 weeks. In all examined specimens, collagen and elastic fibers returned to unexposed-skin levels, and UVA-suppressed collagen synthesis normalized.<\/p>\n

Boisnic S et al. Dermatology. 1999;199(Suppl 1):43\u201348.<\/p>\n

CLINICAL STUDY: ULTRASOUND AND RHEOLOGY<\/b><\/p>\n

Instrumentally measured thickness and elasticity<\/b><\/p>\n

Topical 0.05% retinal significantly increased epidermal thickness and skin elasticity in aging skin, quantified by high-frequency ultrasound and rheology.<\/p>\n

Diridollou S et al. Dermatology. 1999;199(Suppl 1):37\u201341.<\/p>\n

p < 0.01<\/p>\n

Significance reported for increased epidermal thickness and elasticity with 0.05% retinal.<\/p>\n

These findings provide a rationale for firmness and density concepts alongside surface smoothing.<\/p>\n

SIGNALING BEHIND THE STRUCTURE<\/b><\/p>\n

RAR-mediated transcription in epidermal keratinocytes is the main documented pathway. Explant data show matrix recovery consistent with renewed collagen synthesis after UV damage.<\/p>\n

Active retention through stabilization is a formulation prerequisite that requires product-level confirmation.<\/p>\n

Boisnic S et al. Dermatology. 1999;199(Suppl 1):43\u201348 (human skin explants, UVA + 0.05% retinal, 2 weeks). Diridollou S et al. Dermatology. 1999;199(Suppl 1):37\u201341 (0.05% retinal; ultrasound and rheology endpoints).<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Skin tone and pigmentation<\/b><\/h2>\n

MELANIN INDEX AT 12 WEEKS<\/p>\n

\u22126.5%<\/p>\n

A significant reduction in the 0.1% retinal group in the randomized double-blind photoaging trial.<\/p>\n

Kwon HS et al. J Cosmet Dermatol. 2018.<\/b><\/p>\n

The pigment endpoint was significant at 0.1% and not significant at 0.05%. This supports a concentration-specific rather than universal skin-tone claim.<\/p>\n

HOW RETINAL RELATES TO SKIN TONE<\/b><\/p>\n

PIGMENT CLEARANCE THROUGH TURNOVER<\/b><\/p>\n

Accelerated epidermal renewal replaces melanin-containing keratinocytes and reduces surface pigment residence.<\/p>\n

REPORTED DEPIGMENTING ACTIVITY<\/b><\/p>\n

A dedicated study in pigmentary disorders reported measurable depigmenting activity of topical retinal, supporting even-tone formulation development.<\/p>\n

Sorg O et al. Dermatology. 2013;227(3):231\u2013237.<\/p>\n

THE ROLE OF PHOTOSTABILITY<\/b><\/p>\n

The source proposes light-stable inclusion as a way to retain activity in tone-care products intended for daytime use. This performance must be established for the specific complex and formulation.<\/p>\n

POSITIONING<\/p>\n

Combine tone-care evidence with texture and tolerability endpoints to support an even, refined skin appearance. Final product claims require validation.<\/p>\n

Kwon HS et al. J Cosmet Dermatol. 2018;17(3):471\u2013476 (n = 40, 3 months; significant melanin reduction only at 0.1%). Sorg O et al. Dermatology. 2013;227(3):231\u2013237.<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Refined skin: pores and blemish-related mechanisms<\/b><\/h2>\n

The source reports direct antibacterial activity of retinal against Cutibacterium acnes, formerly Propionibacterium acnes, distinguishing it from the retinol and retinoic acid comparators discussed.<\/p>\n

IN VITRO: MINIMUM INHIBITORY CONCENTRATION<\/b><\/p>\n

4\u20138 mg\/L<\/p>\n

Retinal MIC against three P. acnes reference strains.<\/p>\n

COMPARATOR<\/b><\/p>\n

>128 mg\/L<\/p>\n

Retinoic acid MIC against the same strains.<\/p>\n

This activity is attributed to retinal\u2019s aldehyde group, a property of the molecule rather than a finished product.<\/p>\n

Pech\u00e8re M et al. Dermatology. 1999;199(Suppl 1):29\u201331.<\/b><\/p>\n

IN VIVO: SINGLE-BLIND RANDOMIZED STUDY<\/p>\n

The source slide records the median viable-count decrease per cm\u00b2 as \u201c\u2248 \u221210\u00b2 log\u201d after 2 weeks of daily 0.05% retinal. Vehicle alone was ineffective.<\/p>\n

The numerical notation is ambiguous and is retained as written rather than converted to a different unit.<\/p>\n

COMPLEMENTARY EVIDENCE<\/b><\/p>\n

COMEDOLYTIC ACTIVITY<\/p>\n

Topical retinal reduced comedones in the rhino mouse model, providing a complementary mechanism for pore-focused concepts.<\/p>\n

Fort-Lacoste L et al. Dermatology. 1999;199(Suppl 1):33\u201335.<\/p>\n

Use as mechanistic support for clarifying and blemish-prone-skin positioning, rather than a standalone acne-treatment claim.<\/p>\n

Pech\u00e8re M et al. Dermatology. 1999;199(Suppl 1):29\u201331. Fort-Lacoste L et al. Dermatology. 1999;199(Suppl 1):33\u201335. In vitro and animal findings provide mechanistic support, not clinical acne efficacy.<\/p>\n

PART III \u00b7 RETINAL BIOLOGY AND SKIN BENEFITS<\/p>\n

Barrier function, hydration and tolerability<\/b><\/h2>\n

BARRIER FUNCTION: KWON 2018 RANDOMIZED TRIAL<\/b><\/p>\n

\u221214.5%<\/p>\n

TEWL in the 0.1% group<\/p>\n

\u221217.9%<\/p>\n

TEWL in the 0.05% group<\/p>\n

+10.2%<\/p>\n

Skin hydration in the 0.1% group<\/p>\n

+6.0%<\/p>\n

Skin hydration in the 0.05% group<\/p>\n

After 12 weeks of twice-daily retinal use, lower TEWL and greater stratum corneum hydration indicated improvements versus baseline.<\/p>\n

TOLERABILITY UNDER CHALLENGE<\/b><\/p>\n

MAXIMIZED AND LONG-TERM EXPOSURE<\/b><\/p>\n

In a tolerability study with 355 volunteers under maximized and long-term conditions, retinoic acid caused significantly more erythema and scaling, while retinal was closer to vehicle.<\/p>\n

Fluhr JW et al. Dermatology. 1999;199(Suppl 1):57\u201360.<\/p>\n

NO PHOTOTOXICITY SIGNAL<\/b><\/p>\n

A dedicated human tolerability review involving 357 subjects reported a favorable safety profile for topical retinal, including no phototoxic reactions.<\/p>\n

Sachsenberg-Studer EM. Dermatology. 1999;199(Suppl 1):61\u201363.<\/p>\n

MINIMAL SYSTEMIC EXPOSURE<\/b><\/p>\n

Plasma retinoid levels were essentially unchanged after topical use in human skin, supporting local-action positioning.<\/p>\n

Sass JO et al. Skin Pharmacol. 1996;9(5):322\u2013326.<\/p>\n

FORMULATION VALUE<\/p>\n

Tolerability is important for retinoid adherence. The cited barrier and tolerability findings inform the development of everyday retinal products.<\/p>\n

Kwon HS et al. J Cosmet Dermatol. 2018;17(3):471\u2013476. Fluhr JW et al. Dermatology. 1999;199(Suppl 1):57\u201360. Sachsenberg-Studer EM. Dermatology. 1999;199(Suppl 1):61\u201363. Sass JO et al. Skin Pharmacol. 1996;9(5):322\u2013326.<\/p>\n

PART IV \u00b7 SCALP SCIENCE AND HAIRCARE INNOVATION<\/p>\n

The scalp is skin and responds to retinoid signaling<\/b><\/h2>\n

\"\"<\/p>\n

PuriActives\u00ae Crystal Retinal: retinal held within a cyclodextrin inclusion complex.<\/p>\n

Scalp care draws on skincare concepts such as renewal, barrier support and the microbiome. The scalp is a specialized, follicle-rich skin surface with relevant retinoid biology.<\/p>\n

A RETINOID-RESPONSIVE SURFACE<\/p>\n

Scalp epidermis shares retinoid receptor mechanisms with facial skin. The retinal-to-retinoic-acid pathway can operate in keratinocytes across body sites.<\/p>\n

A MICROBIAL DIMENSION<\/p>\n

The follicle-rich scalp carries dense microbial communities, including C. acnes. Retinal\u2019s reported activity against this organism provides a follicular-environment rationale.<\/p>\n

FORMULATION CHALLENGES<\/p>\n

Scalp products are often water-rich, surfactant-containing and transparent, creating stability challenges for unprotected retinal.<\/p>\n

Retinoid skin biology: Saurat JH et al. J Invest Dermatol. 1994;103(6):770\u2013774. Antibacterial activity: Pech\u00e8re M et al. Dermatology. 1999;199(Suppl 1):29\u201331.<\/p>\n

PART IV \u00b7 SCALP SCIENCE AND HAIRCARE INNOVATION<\/p>\n

Follicular biology: interpreting receptor evidence<\/b><\/h2>\n

The follicle is a retinoid-sensitive mini-organ. Receptor genetics defines the biological rationale and the limits of scalp-care positioning.<\/p>\n

GENETIC EVIDENCE: RXR\u03b1 AND THE HAIR CYCLE<\/b><\/p>\n

Keratinocyte RXR\u03b1 is required for a normal hair cycle.<\/b><\/p>\n

Mice with targeted RXR\u03b1 loss in epidermal and follicular keratinocytes developed progressive alopecia and failed to initiate anagen, establishing a requirement for this receptor signaling in the hair cycle.<\/p>\n

Li M et al. Development. 2001;128(5):675\u2013688.<\/p>\n

REVIEW EVIDENCE: THE PILOSEBACEOUS UNIT<\/b><\/p>\n

Retinoids act on follicular glands and epithelium.<\/b><\/p>\n

An endocrine review of pilosebaceous biology discusses retinoid effects on sebocyte differentiation and follicular keratinization, processes relevant to scalp condition, oiliness and scaling.<\/p>\n

Deplewski D, Rosenfield RL. Endocr Rev. 2000;21(4):363\u2013392.<\/p>\n

POSITIONING WITHIN THE EVIDENCE<\/b><\/p>\n

Retinoid effects are dose-dependent, and excessive systemic exposure is associated with hair loss.<\/p>\n

Crystal Retinal\u2019s scalp positioning therefore concerns a balanced, comfortable scalp and follicular environment.<\/p>\n

No hair-growth, density-increase or hair-loss-prevention claim is made or implied.<\/p>\n

TAKEAWAY<\/p>\n

Follicular retinoid sensitivity is established biology; cosmetic development opportunities concern scalp condition.<\/p>\n

Li M et al. Development. 2001;128(5):675\u2013688. Deplewski D, Rosenfield RL. Endocr Rev. 2000;21(4):363\u2013392. Mechanistic evidence, not clinical validation of Crystal Retinal.<\/p>\n

PART IV \u00b7 SCALP SCIENCE AND HAIRCARE INNOVATION<\/p>\n

Scalp-care opportunities from the formulation bench<\/b><\/h2>\n

Premium haircare increasingly uses skincare actives. Retinal development requires stability in realistic scalp formats: water-rich systems with surfactants and potentially prolonged residence.<\/p>\n

THE CHALLENGE<\/b><\/p>\n

Free retinal is difficult to stabilize in scalp formats.<\/b><\/p>\n

Water, oxygen, light and surfactant environments can promote loss of unprotected retinal during product development and storage.<\/p>\n

THE INCLUSION APPROACH<\/b><\/p>\n

A protected guest available at the interface.<\/b><\/p>\n

The inclusion complex reduces exposure of retinal\u2019s conjugated system in the bulk formulation and allows guest exchange at the skin interface through water activity and lipid affinity.<\/p>\n

A BRAND DEVELOPMENT CONCEPT<\/b><\/p>\n

Skincare renewal adapted for the scalp.<\/b><\/p>\n

Scalp comfort, balance, gentle renewal and follicular-environment care are anchored in published skin biology rather than hair-growth promises.<\/p>\n

Stability engineering creates an opportunity to explore retinal in demanding scalp formats.<\/p>\n

PART V \u00b7 FORMULATION AND APPLICATIONS<\/p>\n

Formulating Crystal Retinal: working principles<\/b><\/h2>\n

Inclusion chemistry provides a stabilization rationale, but processing remains important. Confirm each of these eight principles in the customer\u2019s own stability program.<\/p>\n

01 <\/b>ADD DURING COOL-DOWN<\/p>\n

Introduce the complex below typical hot-process temperatures to protect host\u2013guest equilibrium.<\/p>\n

02 <\/b>CONTROL LIGHT FROM THE START<\/p>\n

Use amber or opaque handling through production and filling.<\/p>\n

03<\/b> BUILD ANTIOXIDANT SUPPORT<\/p>\n

Chelators and antioxidant systems remain useful for retinoids, whether included or free.<\/p>\n

04 <\/b>SET pH USING MEASUREMENTS<\/p>\n

Mildly acidic conditions are generally favorable; confirm the suitable window in the final base.<\/p>\n

05 <\/b>SCREEN COMPETING GUESTS<\/p>\n

Hydrophobic fragrance constituents and oils may compete for the cyclodextrin cavity. Check displacement risk in compatibility tests.<\/p>\n

06<\/b><\/p>\n

AVOID STRONG OXIDATIVE CHALLENGES<\/p>\n

Peroxides and aggressive preservative boosters can affect the polyene chain. Screen the full combination.<\/p>\n

07<\/b><\/p>\n

SPECIFY PROTECTIVE PACKAGING<\/p>\n

Airless, low-permeability, light-protective packaging supports shelf-life retention.<\/p>\n

08<\/b><\/p>\n

VALIDATE IN THE REAL FORMULATION<\/p>\n

Run accelerated and real-time stability tests on the finished product. Complex data guide development but do not replace product-level evidence.<\/p>\n

Principles are drawn from retinoid and cyclodextrin literature. PuriPharm technical support can advise on specific bases.<\/p>\n

Loftsson T, Brewster ME. J Pharm Sci. 1996;85(10):1017\u20131025. Yap KL et al. Eur J Pharm Sci. 2005;25(1):49\u201356. These principles are not validated specifications for a particular formulation.<\/p>\n

PART V \u00b7 FORMULATION AND APPLICATIONS<\/p>\n

Skincare concepts informed by the evidence<\/b><\/h2>\n

NIGHT RENEWAL SERUM<\/p>\n

Texture and wrinkle endpoints from randomized studies provide claim-development anchors. Inclusion is intended to support active retention during shelf life.<\/p>\n

Evidence anchors: Kwon 2018; Creidi 1998.<\/p>\n

GENTLE EVERYDAY RETINAL MOISTURIZER<\/p>\n

Barrier findings and vehicle-like tolerability support routine-use development.<\/p>\n

Evidence anchors: Fluhr 1999; Kwon 2018, TEWL and hydration.<\/p>\n

FIRMING AND DENSITY CREAM<\/p>\n

Ultrasound and explant evidence concerning thickness, elasticity and matrix recovery informs firmness concepts.<\/p>\n

Evidence anchors: Diridollou 1999; Boisnic 1999.<\/p>\n

EVEN-TONE SERUM<\/p>\n

Significant melanin-index reduction at 0.1% and reported depigmenting activity support a concentration-specific concept.<\/p>\n

Evidence anchors: Kwon 2018; Sorg 2013.<\/p>\n

CLARIFYING CARE FOR BLEMISH-PRONE SKIN<\/p>\n

C. acnes activity and comedolytic findings provide mechanistic support for pore-focused formulations.<\/p>\n

Evidence anchors: Pech\u00e8re 1999; Fort-Lacoste 1999.<\/p>\n

EYE-AREA RENEWAL CARE<\/p>\n

The source proposes retinal\u2019s efficacy and tolerability profile as a development rationale for thin, sensitive skin around the eyes.<\/p>\n

Evidence anchor: the cited tolerability literature.<\/p>\n

Concepts only. Validate all claims in the final marketed product. Evidence anchors refer to the skin-benefit studies reviewed above.<\/p>\n

PART V \u00b7 FORMULATION AND APPLICATIONS<\/p>\n

Scalp-care concepts<\/b><\/h2>\n

Four dosage-form concepts explore stabilized retinal for scalp care while retaining the limits of the evidence.<\/p>\n

LEAVE-ON SCALP SERUM<\/p>\n

A night-care concept for surface renewal and comfort, informed by retinal epidermal biology and tolerability literature.<\/p>\n

BALANCING TONIC FOR OILY, CONGESTION-PRONE SCALPS<\/p>\n

Reported C. acnes activity and follicular keratinization mechanisms support a clean, balanced follicular-environment concept.<\/p>\n

INTENSIVE PRE-WASH CARE<\/p>\n

A weekly concentrated step in an aqueous base, with active retention as a formulation-development objective.<\/p>\n

CONDITIONER AND HAIR-MASK ADDITION<\/p>\n

Explore rinse-off systems. Guest release and rinse compatibility require joint engineering by the brand and PuriPharm.<\/p>\n

Concepts only. Use scalp-condition wording. The cited evidence does not support hair-growth, density-increase or hair-loss-prevention claims.<\/p>\n

PART V \u00b7 FORMULATION AND APPLICATIONS<\/p>\n

Patent evidence: what the documents show<\/b><\/h2>\n

\"\"<\/p>\n

CN 103987391 B: a granted Chinese patent showing retinal\u2013cyclodextrin acetal conjugate structures.<\/p>\n

\"\"<\/p>\n

CN 103987391 B patent family: exocyclic retinal\u2013cyclodextrin hemiacetal structure (VIII).<\/p>\n

\"\"<\/p>\n

CN 103987391 B patent family: endocyclic structure (VII).<\/b><\/p>\n

INTERPRETING THE RECORD<\/p>\n

Patent documents cover both noncovalent inclusion complexes and covalent conjugates. PuriActives\u00ae Crystal Retinal is positioned as a molecular inclusion complex based on physical equilibrium. Related patent test data are discussed in the stability and patent-history sections.<\/p>\n

Figures reproduced from granted patent documents for technical discussion: CN 103987391 B; the source also cites the US 10,864,148 B2 family. Patent structures and comparisons are not product specifications for Crystal Retinal.<\/p>\n

PART VI \u00b7 COMMERCIAL POSITIONING<\/p>\n

One ingredient, four value pillars<\/b><\/h2>\n

MOLECULAR STABILIZATION<\/b><\/p>\n

Cyclodextrin inclusion reduces environmental exposure of retinal\u2019s conjugated system, informed by host\u2013guest chemistry and retinoid-stabilization patents.<\/p>\n

EFFICACY INFORMED BY RETINOIC ACID COMPARISONS<\/b><\/p>\n

One metabolic step from the active form, with randomized cosmetic-concentration studies on texture, wrinkles, barrier function, hydration and pigmentation.<\/p>\n

FORMULATION FLEXIBILITY<\/b><\/p>\n

Inclusion enables exploration of creams, aqueous serums and scalp formats, with guest release at the skin interface as the development rationale.<\/p>\n

A DOCUMENTED SCIENTIFIC STORY<\/b><\/p>\n

Peer-reviewed clinical literature, patent tests and receptor biology provide a framework for claim development and review.<\/p>\n

PRODUCT & PARTNERSHIP<\/p>\n

Retinal science. The possibilities of molecular inclusion.<\/b><\/h2>\n

\"\"<\/p>\n

PuriActives\u00ae Crystal Retinal Cyclodextrin-Included Retinal combines a direct cosmetic retinoid precursor with molecular stabilization for skin and scalp formulation development.<\/p>\n

PuriPharm Co., Ltd.<\/p>\n

PuriActives\u00ae Crystal Retinal \u00b7 INCI: RETINAL<\/p>\n

Samples, technical documentation and development support available on request.<\/p>\n

www.puriactives.com<\/p>\n

This report is intended for professionals and summarizes published research and granted patent documents. Data characterize the retinal active class and the cited test materials. Finished-product claims require product-level validation.<\/p>\n","protected":false},"excerpt":{"rendered":"

PuriActives\u00ae Crystal RetinalCyclodextrin-Included Retin […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[],"_links":{"self":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2398"}],"collection":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2398"}],"version-history":[{"count":1,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2398\/revisions"}],"predecessor-version":[{"id":2431,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/2398\/revisions\/2431"}],"wp:attachment":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2398"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}